tiakis Biotech AG Participates in KOL webcast on Pulmonary Arterial Hypertension (PAH)
April 2025 –
tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced its participation in a Tru-Talks KOL webcast moderated by Srikripa Devarakonda, Biotech Equity Analyst at Truist Securities.
The Tru-Talk hosted seasoned medical expert Prof. Dr. Roham Zamanian, Stanford University Medical Center, Pulmonary and Critical Care Medicine, and Martin Voss, CEO of tiakis, covering topics of the current pulmonary arterial hypertension (PAH) treatment landscape, shortcomings of the current standard of care and how Tiprelestat, a Phase II-ready anti-inflammatory and tissue protective drug candidate, could close the gap towards demonstrating disease modification potential.
Tiprelestat is a clinical-stage recombinant protein that mitigates the pathologic overactivity of certain enzymes involved in inflammation, tissue remodeling, and immune responses.
A link to the webcast is available for 30 days through the news section on tiakis’ homepage https://tiakis.bio/news or on Truist Securities' website https://truist-tru-talks-spotlighting-pah-with-mar-2025.open-exchange.net/ (please quote Srikripa Devarakonda as Truist Representative for purposes of registration).
About tiakis Biotech
tiakis Biotech AG is an innovative, clinical-stage pharmaceutical company specializing in groundbreaking approaches to protect human tissues and organ structures. The Company develops anti-inflammatory treatments to prevent severe organ damage and failure, particularly after invasive surgeries, with a primary focus on pulmonary arterial hypertension (PAH). tiakis´ lead candidate Tiprelestat is in clinical development and addresses unmet medical needs in life-threatening conditions. The Company is based in Kiel, Germany.
Contact
tiakis BIOTECH AG
Sophienblatt 40
24103 Kiel
Germany
phone: +49 431 8888-462
fax: +49 431 8888-463
email: info@tiakis.bio